Mallinckrodt plc Ordinary Share (NYSE:MNK):
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in West Virginia.
The company is down by -2.63 percent from yesterday’s close.
Shares last traded at $61.38 a tad under $69.45, the 50 day moving average and which is slightly below the 200 day moving average of $66.80. The 50 day moving average was down by -11.62% whereas the 200 day average was down by -8.12%.
The P/E ratio is 11.57 and the market cap of the company is 6.61B. As of the latest earnings report the EPS was $5.30 and is estimated to be $7.64 for the current year with 107,713,000 shares now outstanding. Analysts expect next quarter’s EPS will be $1.90 with next year’s EPS anticipated to be $8.09.
Brokerage analysts have released opinions on MNK of late. On August 31 Deutsche Bank maintained a stock rating of “Buy” and lowered the price target to $84.00 from $87.00. August 25 investment analysts at Barclays made no change to the stock rating of “Overweight” but moved up the price target from $80.00 to $112.00.
On August 24 Piper Jaffray left the company rating at “Overweight” and moved up the price target from $102.00 to $112.00. Stifel Nicolaus began coverage giving it an initial rating of “Buy”.
Equity analyst BMO Capital started coverage with an initial rating of “Outperform”. On May 4 JP Morgan left the stock rating at “Neutral” and lowered the price expectation to $85.00 from $120.00.